TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03450200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises for diabetic peripheral neuropathy
Description: Hands, fingers, and foot exercises for diabetic peripheral neuropathy to improve activities of daily living, and decreases the signs and symptoms of DPN

Intervention type: OTHER
Group type: OTHER
Intervention: Health education for diabetic foot care
Description: Health education for daily diabetic foot care to prevent diabetic foot ulcer was provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education for diabetic foot care
Description: Health education for daily diabetic foot care to prevent diabetic foot ulcer was provided.
Study: NCT02624258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 RNA redirected autologous T-cells (RNA CART19 cells)
Description: Subjects will be treated with IV administration of RNA anti-CD19 CAR T cells for a total of six doses over 3 weeks. The first dose will be administered 1-4 days after infusion of cyclophosphamide 30mg/kg.
Study: NCT03593876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training
Description: This study will use an adapted form of strategy training for people with communication impairments.
Study: NCT01643616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine 1%
Description: 20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine 1%
Description: 20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75%
Description: 10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75%
Description: 10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine 1%
Description: 10ml Prilocaine 1% for saphenous nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine 1%
Description: 10ml Prilocaine 1% for saphenous nerve block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guidance
Description: In group US the sciatic nerve localization and needle guidance is realized using ultrasound.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nerve stimulation technique
Description: In the group NS sciatic nerve localization and needle guidance is realized using nerve stimulation technique. However, ultrasound is used observing (Observer) the procedure, but blinded for the physician (Anesthetist) performing the block.
Study: NCT03068624

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD8+ SLC45A2-specific T Lymphocytes
Description: Given via hepatic arterial infusion via central catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study: NCT03097679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsar Stent
Description: Percutane transluminal stent angioplasty with a Pulsar Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LifeStent Flexstar Vascular Stent
Description: Percutane transluminal stent angioplasty with a LifeStent Flexstar Vascular Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
Study: NCT03570437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 on three days in a 28 day cycle (with 6 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 on three days in a 28 day cycle (with 6 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: 20 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: 20 mg per day
Study: NCT00469768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine reservoir intravaginal ring
Description: a silicone elastomer reservoir ring containing 25mg of dapivirine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine matrix intravaginal ring
Description: a silicone elastomer matrix intravaginal ring containing 25mg of dapivirine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo intravaginal ring
Description: a silicone elastomer intravaginal ring containing no dapivirine
Study: NCT02030132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Feedback
Description: Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Feedback
Description: Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Feedback
Description: Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Feedback
Description: Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
Study: NCT01643681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Tissue derived MSCs Transplantation
Description: Into lumbar intervertebral disc infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4x10e7 cells/1mL
Study: NCT02097784

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Echocardiography
Study: NCT01176760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase 4 (DPP 4) inhibitor
Description: One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase 4 (DPP 4) inhibitor
Description: One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase 4 (DPP 4) inhibitor
Description: One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral glucose
Description: 50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral glucose
Description: 50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral glucose
Description: 50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.
Study: NCT03353623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Serious Game
Description: Serious Game (SG) refers to the use of immersive virtual environments and wearable haptic devices during the treatment. Two SG were specifically developed to allow a playful training of different, targeted Upper Limb (UL) movement based on typical rehabilitation exercises (reach-to-grasp, linear path tracking, hand orientation). The child interacts directly with a virtual environment through haptic feedback provided to his/her fingertips. In particular, moneybox game focused on pincer grasp and reaching tasks with pronation/supination od the hand while marble labyrinth game focused on pointing and tracking movements requiring both eye-hand and upper limb inter-joint coordination.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Serious Game
Description: Serious Game (SG) refers to the use of immersive virtual environments and wearable haptic devices during the treatment. Two SG were specifically developed to allow a playful training of different, targeted Upper Limb (UL) movement based on typical rehabilitation exercises (reach-to-grasp, linear path tracking, hand orientation). The child interacts directly with a virtual environment through haptic feedback provided to his/her fingertips. In particular, moneybox game focused on pincer grasp and reaching tasks with pronation/supination od the hand while marble labyrinth game focused on pointing and tracking movements requiring both eye-hand and upper limb inter-joint coordination.
Study: NCT03557866

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: running
Description: individuals will be asked to run for 5 km in self selected speed

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: running
Description: individuals will be asked to run for 5 km in self selected speed
Study: NCT00901303

Intervention type: DRUG
Group type: OTHER
Intervention: ABVD chemotherapy
Description: Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: ABVD chemotherapy
Description: Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle
Study: NCT03817489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin qigong
Description: The intervention consists of eight sequential forms of movements which is practiced with guidance on rhythmic breathing and mindful awareness. Each cycle of the eight movements requires 10 to 15 minutes for completion. Four cycles will be practiced in each session with short breaks arranged between them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: The intervention is developed based on the core components of the established Mindfulness-Based Stress Reduction and the Mindful Self-Compassion program with adaptation for local practice. The focus of the group is to nurture mindful awareness, acceptance, and self-compassion. The group sessions are composed of a combination of mindfulness-based practice, relaxation, and yoga exercise. The basic philosophy of this intervention is the emphasis of the nurturing of self-kindness attitude, and non-attachment attitude towards inter-personal connectedness and letting go of self-criticism, need for control, and defensive separation in times of adversity. Short breaks will be arranged between each practice.
Study: NCT02432430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage
Description: Quality improvement technical support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage
Description: Financial incentives to support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
Study: NCT00891150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.~Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.~Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.~Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min).
Study: NCT05157087

Intervention type: DRUG
Intervention: Omalizumab
Description: Omalizumab use was analyzed in two categories. First, initiators were defined as individuals with ≥ 1 omalizumab prescription. Responders were defined as individuals with at least 4 administrations of omalizumab.

Intervention type: DRUG
Intervention: Omalizumab
Description: Omalizumab use was analyzed in two categories. First, initiators were defined as individuals with ≥ 1 omalizumab prescription. Responders were defined as individuals with at least 4 administrations of omalizumab.
Study: NCT02799550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic CART-19
Description: allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
Study: NCT00487981

Intervention type: DEVICE
Group type: OTHER
Intervention: Precision Spinal Cord Stimulation
Description: Stimulation on throughout the study once device is implanted
Study: NCT04179110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and Ramucirumab
Description: Patients will receive Pembrolizumab 200 mg \& Ramucirumab 10 mg/kg every 3 weeks.
Study: NCT03353623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: Conventional therapy (CONV) refers to the neurocognitive rehabilitation approach, with the purpose of improving pointing, tracking, reaching and grasping, and pronation/supination of the forearm. The therapeutic sessions were performed with the exception of the visual channel to ensure that the child focused his/her attention on tactile/kinesthetic information to complete the task. In particular, five different tasks have been proposed during the sessions: 1) recognize trajectories; 2) arm proprioception; 3) object manipulation; 4) recognize surfaces; 5) forearm orientation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: Conventional therapy (CONV) refers to the neurocognitive rehabilitation approach, with the purpose of improving pointing, tracking, reaching and grasping, and pronation/supination of the forearm. The therapeutic sessions were performed with the exception of the visual channel to ensure that the child focused his/her attention on tactile/kinesthetic information to complete the task. In particular, five different tasks have been proposed during the sessions: 1) recognize trajectories; 2) arm proprioception; 3) object manipulation; 4) recognize surfaces; 5) forearm orientation.
Study: NCT01385592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02869724

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weekly divided delivery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monthly divided delivery
Study: NCT03510130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine leg movement
Description: Routine leg movement to the right and left in the supine position during the second stage of labor, for 3 minutes every 20-30 minutes by the attending physician or nurse.
Study: NCT01659450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low energy dense
Description: This group received a diet appropriate with their weight in the form of low energy density diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: This group received a diet appropriate with their weight in the form of an usual diet regarding the energy density.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: Calorie requirements of each subject were estimated based on resting energy expenditure (by the use of Harris-Benedict equation) and physical activity levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: Calorie requirements of each subject were estimated based on resting energy expenditure (by the use of Harris-Benedict equation) and physical activity levels.
Study: NCT03492047

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low dose N-acetylcysteine
Description: N-acetylcysteine 600mg twice daily
Study: NCT03762551

Intervention type: OTHER
Group type: OTHER
Intervention: skin biopsy
Description: Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: skin biopsy
Description: Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.
Study: NCT04469621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443122
Description: Pharmaceutical form:capsule Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:capsule Route of administration: oral
Study: NCT04397445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Ranitidine 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Ranitidine 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low nitrite/NDMA meals
Description: Meals containing low levels of nitrites and NDMA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low nitrite/NDMA meals
Description: Meals containing low levels of nitrites and NDMA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High nitrite/NDMA meals
Description: Meals containing higher levels of nitrites and NDMA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High nitrite/NDMA meals
Description: Meals containing higher levels of nitrites and NDMA
Study: NCT02647736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion
Study: NCT05084664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: premodulated current+ exercises

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: diadynamic current+ exercises
Study: NCT00232271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clexane
Study: NCT04527653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel
Description: Non-invasive thermo-mechanical treatment
Study: NCT04178265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: needles were inserted to Kunlun(BL60), Yanglingquan (GB34), Sanyinjiao(SP6), Taixi (KI 3) contralateral to the operated leg and deqi sensation elicited at acupoints.
Study: NCT01121666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin alfa
Description: 150IU per day subcutaneously for a maximum of 16 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa
Description: 150IU per day subcutaneously for a maximum of 16 days
Study: NCT04699526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Universal Prevention Curriculum Training for Schools
Description: School administrators and teachers participated in UPC training and formed prevention leadership action teams
Study: NCT00354250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ispinesib
Description: Given IV
Study: NCT03492047

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high dose N-acetylcysteine
Description: N-acetylcysteine 1200mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80mg /m2 IV
Study: NCT03250676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3B-6545
Description: Oral capsules by mouth once daily
Study: NCT03492047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80mg /m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80mg /m2 IV